Reimbursement decision-making system in Poland systematically compared to other countries

被引:2
|
作者
Mela, Aneta [1 ]
Rdzanek, Elzbieta [1 ]
Jaroszynski, Janusz [2 ]
Furtak-Niczyporuk, Marzena [3 ]
Jablonski, Miroslaw [4 ]
Niewada, Maciej [1 ]
机构
[1] Med Univ Warsaw, Ctr Preclin Res & Technol CePT, Dept Expt & Clin Pharmacol, Warsaw, Poland
[2] Marie Curie Sklodowska Univ, Fac Law & Adm, Dept Adm Proceedings, Lublin, Poland
[3] Med Univ Lublin, Dept Publ Hlth, Lublin, Poland
[4] Med Univ Lublin, Dept Orthopead & Rehabil, Lublin, Poland
关键词
reimbursement decision-making systems; Polish Agency for Health Technology Assessment Tariffication; HTA agencies; systematic review; reimbursement recommendations; HEALTH TECHNOLOGY-ASSESSMENT; ASSESSMENT RECOMMENDATIONS; DRUG REIMBURSEMENT; THERAPIES; FRANCE; ECONOMICS; AGENCIES; OUTCOMES; ACCESS; IMPACT;
D O I
10.3389/fphar.2023.1153680
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Our objective was to analyze and compare systematically and structurally reimbursement systems in Poland and other countries.Methods: The systems were selected based on recommendations issued by the Polish Agency for Health Technology Assessment and Tariffication (AHTAPol), which explicitly referred to other countries and agencies). Consequently, apart from Poland, the countries included in the analysis were England, Scotland, Wales, Ireland, France, Netherlands, Germany, Norway, Sweden, Canada, Australia and New Zealand. Relevant information and data were collected through a systematic search of PubMed (Medline), Embase and The Cochrane Library as well as competent authority websites and grey literature sources.Results and discussion: In most of the countries, the submission of a reimbursement application is initiated by a pharmaceutical company, and only a few countries allow it before a product is approved for marketing. All of the agencies analyzed are independent and some have regulatory function of reimbursement decision making body. A key criterion differentiating the various agencies in terms of HTA is the cost-effectiveness threshold. Most of the countries have specific mechanisms to improve access to expensive specialty drugs, including cancer drugs and those used for rare diseases. Reimbursement systems often lack consistency in appreciating the same stages, leading to heterogeneous decision-making processes. The analysis of recommendations issued in different countries for the same medicinal product will allow a better understanding of the relations between the reimbursement system, HTA assessment, stakeholders involvement and decision on reimbursement of innovative drugs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Epidemiology of penile cancer in Poland compared to other European countries
    Wnetrzak, Iwona
    Czajkowski, Mateusz
    Baranska, Klaudia
    Miklewska, Marta
    Wojciechowska, Urszula
    Sosnowski, Roman
    Didkowska, Joanna A.
    CANCER MEDICINE, 2024, 13 (16):
  • [32] The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin
    Andrej Janzic
    Igor Locatelli
    Mitja Kos
    American Journal of Cardiovascular Drugs, 2017, 17 : 399 - 408
  • [33] The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin
    Janzic, Andrej
    Locatelli, Igor
    Kos, Mitja
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (05) : 399 - 408
  • [34] DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICING
    Lemeshko, V
    Fedyaeva, V
    Musina, N. Z.
    Omelyanovskiy, V
    Khachatryan, G. R.
    VALUE IN HEALTH, 2018, 21 : S185 - S185
  • [35] IDENTIFICATION OF IMPORTANT CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING AND THEIR RELATIVE IMPORTANCE
    Funagoshi, M.
    Murasawa, H.
    Shimozuma, K.
    VALUE IN HEALTH, 2017, 20 (09) : A661 - A661
  • [36] IMPACT OF HEALTH CARE REFORM ON DRUG REIMBURSEMENT DECISION-MAKING IN TAIWAN
    Lai, L.
    Eccles, T.
    Heemstra, L.
    Van Engen, A.
    VALUE IN HEALTH, 2014, 17 (07) : A661 - A661
  • [37] CALCULATION OF DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN SIMPLIFIED PROCEDURE IN HUNGARY
    Nagy, Z.
    Molnar, M. P.
    Sebestyen, A.
    Kriszbacher, I
    Agoston, I
    Vas, G.
    Varga, S.
    Boncz, I
    VALUE IN HEALTH, 2009, 12 (07) : A239 - A240
  • [38] Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes
    Wilk, N.
    Wierzbicka, N.
    Skrzekowska-Baran, I.
    Mocko, P.
    Tomassy, J.
    Kloc, K.
    PUBLIC HEALTH, 2017, 145 : 51 - 58
  • [39] Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
    Andreja Detiček
    Andrej Janzic
    Igor Locatelli
    Mitja Kos
    BMC Health Services Research, 18
  • [40] What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries
    Maynou, Laia
    Cairns, John
    HEALTH POLICY, 2019, 123 (02) : 130 - 139